July 8, 2020

Menicon Co., Ltd.
President and CEO: Hidenari Tanaka
Securities Code: 7780
TSE, 1st section, NSE, 1st section
Contact:
Motonari Watanabe
Senior Executive Officer,
Corporate Management, CFO
Phone: +81-52-935-1646

Notice Regarding a business tie-up agreement concluded with China's Wenzhou Medical University

Menicon Co., Ltd. hereby announces that on June 30, 2020, it concluded a business tie-up agreement for the myopia progression suppression sector and the research and development of orthokeratology lenses etc. with Wenzhou Medical University Eye Hospital and School of Ophthalmology & Optometry, which have outstanding research track records in the field of ophthalmology in China. For details, please refer to the follows.

End.

July 8, 2020
Menicon Co., Ltd.

A business tie-up agreement concluded with China's Wenzhou Medical University



Wenzhou Medical University Eye Hospital in China

On Tuesday, June 30, 2020, Menicon Co., Ltd. concluded a business tie-up agreement with Wenzhou Medical University Eye Hospital and School of Ophthalmology & Optometry (hereinafter "WMU"), which have outstanding research track records in the field of ophthalmology in China.

WMU was established in 1958. At present, it owns national platforms such as the Visual Science Research and Ophthalmology Disease Clinical Center, as well as the Myopia Diagnosis and Treatment Technical Center certified by the Ministry of Education of the People's Republic of China*. It is China's top-level educational institution for clinical medicine, education, and research in the field of ophthalmology.

Menicon has cooperated with WMU for over ten years and has worked to spread and develop contact lenses in China. On this occasion, as Menicon made Wenzhou FocuSee Vision Care Technologies—a contact lenses

manufacturing company established by WMU—its wholly-owned subsidiary, the two companies reinforced their relationship further, and finalized a new business tie-up agreement, aimed at the growth and development of ophthalmology treatment in China. Major tie-ups include the following.

- Interchanges in the field of clinical research of special contact lenses, and development of products
- Fostering and training of medical specialists and students for prescribing special contact lenses
- Interchanges in the field of advanced medicine, for example, suppression of myopia progression, and remote diagnosis/treatment

With this tie-up, Menicon will work in unison with China’s top scientific research institution to focus on the myopia progression suppression sector, which has been extensively studied in recent years, and promote (a) the research and development of special contact lenses such as orthokeratology lenses and lenses for irregular corneas and (b) the development of programs to educate and train physicians to prescribe these lenses to patients. By so doing, we will accelerate the R&D and spread of Menicon Group’s products in the Chinese ophthalmology market.

*The Ministry of Education of the People's Republic of China: An organization that corresponds to Japan’s Ministry of Education, Culture, Sports, Science and Technology.

End